Menu
← Oncology Approval Tracker
FDA DECISION ·
Reblozyl
luspatercept-aamt · Celgene / Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For anemia in adults with very low- to intermediate-risk MDS who have not received an erythropoiesis-stimulating agent and may require regular red blood cell transfusions.
LAMPGEN ANALYSIS
Why it matters
The action broadened anemia treatment to patients without prior ESA exposure.
What research teams should watch
Document risk category, ESA history and transfusion baseline before assessing the response to therapy.
PRIMARY RECORDS